. Author manuscript; available in PMC: 2009 Sep 21.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2008 Jan 17;28(4):739–745. doi: 10.1161/ATVBAHA.107.160085

Table 1.

Serum concentrations of inflammatory markers for 20 HD patients before and after a single HD session with or without FIR therapy.

	HD session without FIR	HD session with FIR
hsCRP (mg/L)-BHD	4.10±4.07	4.63±4.32
hsCRP (mg/L)-AHD	4.34±4.26^*	3.98±2.93
Δ (AHD-BHD) hsCRP (mg/L)	0.24±0.43	−0.65±1.73^†
sICAM-1 (ng/mL)-BHD	690±225	728±218
sICAM-1 (ng/mL)-AHD	886±281^*	823±320^*
Δ (AHD-BHD) sICAM (ng/mL)	196±128	95±190^†
sVCAM-1 (ng/mL)-BHD	1135±664	1164±676
sVCAM-1 (ng/mL)-AHD	1461±716^*	1243±667^*^†
Δ (AHD-BHD) sVCAM-1 (ng/mL)	326±249	79±107^†

hsCRP, hypersensitive C-reactive protein; BHD, before hemodialysis; AHD, after hemodialysis; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1

Values are expressed as the mean ± SD.

Statistically significant effect of HD.

^†

Statistically significant effect of FIR therapy.